As for the previous MI patients or multivessel SCAD patients without overt inflammation (median hs-CRP level 1.6 mg/L at entry), anti-inflammatory methotrexate treatment is ineffective at reducing the cardiovascular events (57). The gene discussed is CRP; the disease is myocardial infarction.